India, March 21 -- Shares of Alnylam Pharmaceuticals, Inc. (ALNY) gained 10% after the RNAi therapeutics company announced the U.S. Food and Drug Administration approval of the supplemental New Drug Application (sNDA) for its RNAi therapeutic, Amvuttra (vutrisiran), for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits.
ALNY is currently trading at $280.44, up $26.90 or 10.61%, on the Nasdaq. The stock opened its trading at $261.82 after closing Thursday at $253.54. The stock has traded between $141.98 and $304.39 in the past 52-week period.
The approval expands the indicat...